Description
Lisinopril is an enalapril analog that inhibits angiotensin-converting enzyme (ACE), exhibiting antihypertensive, cardioprotective, and anti-fibrotic activities. Lisinopril is clinically used to treat hypertension, congestive heart failure (CHF), myocardial infarction, and retinal disorders associated with diabetes. In vivo, lisinopril decreases matrix metalloproteinase 2 (MMP2) activity, inhibits left ventricular dilation, and suppresses myocardial hypertrophy, preventing changes in contractility. In other animal models, this compound decreases hydroxyproline levels and inhibits paraquat-induced lung fibrosis.
References
Brower GL, Levick SP, Janicki JS. Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure. Am J Physiol Heart Circ Physiol. 2007 Jun;292(6):H3057-64. PMID: 17308006.
Mohammadi-Karakani A, Ghazi-Khansari M, Sotoudeh M. Lisinopril ameliorates paraquat-induced lung fibrosis. Clin Chim Acta. 2006 May;367(1-2):170-4. PMID: 16458281.
Goa KL, Balfour JA, Zuanetti G. Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction. Drugs. 1996 Oct;52(4):564-88. PMID: 8891468.
Apostolakis S, Krambovitis E, Vlata Z, et al. CX3CR1 receptor is up-regulated in monocytes of coronary artery diseased patients: impact of pre-inflammatory stimuli and renin-angiotensin system modulators. Thromb Res. 2007;121(3):387-395. PMID: 17521710.
